{"id":53118,"date":"2026-01-06T22:27:21","date_gmt":"2026-01-06T14:27:21","guid":{"rendered":"https:\/\/flcube.com\/?p=53118"},"modified":"2026-01-06T22:27:22","modified_gmt":"2026-01-06T14:27:22","slug":"nmpa-releases-draft-102nd-reference-preparations-list-for-generic-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53118","title":{"rendered":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs"},"content":{"rendered":"\n<p>The <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> released the <strong>102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs<\/strong> (draft for public comment), which will remain open for review until <strong>January\u202f16, 2026<\/strong>. The list includes <strong>9 new drug specifications<\/strong>, <strong>20 supplemental additions<\/strong>, and <strong>14 specifications that failed review<\/strong> due to insufficient safety and efficacy data.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-list-summary\">List Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Count<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>New Inclusions<\/strong><\/td><td>9 specifications<\/td><td>First\u2011time entry into RLD list<\/td><\/tr><tr><td><strong>Supplemental Additions<\/strong><\/td><td>20 specifications<\/td><td>Added to existing RLD entries<\/td><\/tr><tr><td><strong>Failed Review<\/strong><\/td><td>14 specifications<\/td><td>Rejected due to inadequate safety\/efficacy data<\/td><\/tr><tr><td><strong>Public Comment Period<\/strong><\/td><td>Jan\u202f5\u202f\u2013\u202fJan\u202f16, 2026<\/td><td>Draft open for stakeholder feedback<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-context-amp-market-impact\">Regulatory Context &amp; Market Impact<\/h2>\n\n\n\n<p><strong>Reference Preparations List<\/strong>: The RLD list identifies <strong>innovator products<\/strong> and <strong>benchmark generics<\/strong> that serve as <strong>bioequivalence standards<\/strong> for domestic manufacturers seeking <strong>generic drug approval<\/strong> in China.<\/p>\n\n\n\n<p><strong>Key Implications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>New Inclusions (9 specs)<\/strong>: Create <strong>immediate opportunities<\/strong> for domestic generic manufacturers to develop <strong>copycat versions<\/strong> of previously unreferenced drugs, potentially <strong>reducing costs<\/strong> and <strong>expanding patient access<\/strong><\/li>\n\n\n\n<li><strong>Supplemental Additions (20 specs)<\/strong>: Clarify and expand existing RLD entries, <strong>streamlining<\/strong> the development pathway for <strong>complex generics<\/strong> (e.g., extended\u2011release formulations)<\/li>\n\n\n\n<li><strong>Failed Review (14 specs)<\/strong>: Highlights <strong>NMPA\u2019s tightening standards<\/strong> for safety and efficacy data, <strong>raising the bar<\/strong> for future RLD submissions<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>: Each new RLD inclusion can unlock a <strong>\u00a5200\u2011500\u202fmillion<\/strong> (US$28\u201170\u202fmillion) generic market opportunity within <strong>2\u20113 years<\/strong> of approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-failed-review-analysis\">Failed Review Analysis<\/h2>\n\n\n\n<p><strong>Primary Reasons for Rejection<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Insufficient clinical data<\/strong>: Lack of robust <strong>Phase\u202fIII trials<\/strong> in Chinese populations<\/li>\n\n\n\n<li><strong>Safety concerns<\/strong>: Unresolved <strong>adverse event signals<\/strong> in post\u2011marketing surveillance<\/li>\n\n\n\n<li><strong>Efficacy gaps<\/strong>: <strong>Non\u2011inferiority margins<\/strong> not met vs. international reference standards<\/li>\n<\/ul>\n\n\n\n<p><strong>Therapeutic Areas Affected<\/strong>: Primarily <strong>cardiovascular, CNS, and anti\u2011infective<\/strong> drugs, where safety margins are particularly stringent.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the finalization of the 102nd RLD list, its impact on generic drug development timelines, and market opportunities for domestic manufacturers. Actual results may differ materially due to public comment feedback, regulatory review adjustments, and competitive dynamics in the generic drug sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[102],"class_list":["post-53118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-cde"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53118\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53118\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T14:27:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T14:27:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs\",\"datePublished\":\"2026-01-06T14:27:21+00:00\",\"dateModified\":\"2026-01-06T14:27:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0605.webp\",\"keywords\":[\"CDE\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53118#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53118\",\"name\":\"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0605.webp\",\"datePublished\":\"2026-01-06T14:27:21+00:00\",\"dateModified\":\"2026-01-06T14:27:22+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53118\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0605.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0605.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53118#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53118","og_locale":"en_US","og_type":"article","og_title":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs","og_description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.","og_url":"https:\/\/flcube.com\/?p=53118","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T14:27:21+00:00","article_modified_time":"2026-01-06T14:27:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53118#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53118"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs","datePublished":"2026-01-06T14:27:21+00:00","dateModified":"2026-01-06T14:27:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53118"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53118#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","keywords":["CDE"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53118#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53118","url":"https:\/\/flcube.com\/?p=53118","name":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53118#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53118#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","datePublished":"2026-01-06T14:27:21+00:00","dateModified":"2026-01-06T14:27:22+00:00","description":"The Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) released the 102nd List of Reference Preparations (RLDs) for Chemical Generic Drugs (draft for public comment), which will remain open for review until January\u202f16, 2026. The list includes 9 new drug specifications, 20 supplemental additions, and 14 specifications that failed review due to insufficient safety and efficacy data.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53118#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53118"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53118#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","width":1080,"height":608,"caption":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53118#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0605.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53118"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53118\/revisions"}],"predecessor-version":[{"id":53122,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53118\/revisions\/53122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53121"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}